ArticleCell reports. Medicine2026
Self-assembly of tumor-related vascularized colorectal tumoroid-on-a-chip for precision medicine drug testing.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Vascularization in Tumor Organoid and Tumor-on-Chip Models: Evidence Requirements for Attributing Therapy-Resistance Mechanisms.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complexity of tumors cannot be accurately simulated by current tumoroid models. One of these limitations is poor vascularization in current tumor models, particularly the lack of tumor-specific blood vessels. Therefore, it is challenging to have a thorough discussion of many in vitro studies regarding the tumor vascular environment. To overcome this limitation, this study combines tumoroid and microfluidic technologies to develop a vascularized tumoroid-on-a-chip. This physiologically relevant colorectal tumoroid-on-a-chip enables self-assembly of tumor-associated vasculature and provides stable perfusion. It has the potential to better simulate the complex vascular environment of colorectal cancer, allowing for more accurate assessment. This study confirms the effectiveness of this model and verifies the variation in the response of tumoroid-on-a-chip models from different patients to FOLFOX plus bevacizumab. It also tests the sensitivity of several small-molecule anti-angiogenic drugs. These validations provide preliminary evidence supporting the reliability of the model and its potential utility in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.